Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C

Kazuhiko Mishima, Haruhiko Fukuda(National Cancer Center Hospital East), Nobuyoshi Sasaki(Kyorin University), Hikaru Sasaki(Tokyo Dental College Ichikawa General Hospital), Tomoyuki Koga(University of Minnesota), Ryo Nishikawa(Kanazawa Hospital), Yasutomo Momii(Oita University), Naoki Shinojima, Manabu Natsumeda(Niigata University), Minako Sumi(Tokyo Metropolitan Geriatric Hospital), Junki Mizusawa(Japan Clinical Cancer Research Organization), Atsushi Sasaki(Saitama Medical University), Miho Gomyo(Kyorin University), Kenichiro Asano(Hirosaki University), Yoshiki Arakawa(Kyoto Prefectural University of Medicine), Koji Yoshimoto(Kyushu University), Kazuhiro Tsuchiya(Kyorin University), Takao Tsurubuchi(University of Tsukuba), Akio Asai(Kansai Medical University), Fumiyuki Yamasaki(Hiroshima University), Ichiyo Shibahara(Kitasato University), Jun‐ichi Tamaru(Social Insurance Saitama Chuo Hospital), Motoo Nagane(Kyorin University), Manabu Kinoshita(Brigham and Women's Hospital), Yoshitaka Narita(Unknown), Masaru Kojima(Dokkyo University), Kayoko Abe(Hirosaki University), Hiroshi Katayama(National Cancer Center), Shigeo Nakamura(University of the Ryukyus), Takashi Sasayama(Himeji Medical Center)
Neuro-Oncology
November 4, 2022
Cited by 29


Related Papers